Additionally, our data show that approximately 90% of SCLC tumors (George et al. 2015; George et al. 2024) express OC2 (Supplementary Fig. 5C) suggesting that a significant proportion of SCLC patients could potentially benefit from OC2 inhibition therapy. This evidence concerns the gene ONECUT2 and small cell lung carcinoma.